Search Results

). However, in the eligible study population, a 3.2-month improvement in OS was observed with PGC (HR, 0.82; P =.03). Despite this improvement, the incidence of thrombocytopenia, bleeding, and febrile neutropenia were all greater with the 3-drug combination

-EPOCH-R at 24 academic centers, 3-year EFS was 86% (95% CI, 80.3%–91.5%). 27 Although pediatric EFS rates are less than those seen in adults, the DA-EPOCH-R regimen (without radiation) has fewer acute toxicities, including less stomatitis, enteritis, febrile

-stimulating factor, granulocyte colony-stimulating factor) can ameliorate chemotherapy-induced myelosuppression and reduce the incidence of febrile neutropenia, but cumulative thrombocytopenia remains dose-limiting. Although trials involving patients with SCLC were

% and 96%, respectively. The corresponding rates for 3-year OS were 92% and 100%, respectively. The incidence of febrile neutropenia was 20% and 8% in the 2 cohorts, respectively. The phase I regimen served as the basis for the currently active phase III

years; range, 1–20 years), the response rate (CR + CRp) was 20%. 77 Single-agent clofarabine in this setting was associated with severe liver toxicities (generally reversible) and frequent febrile episodes, including grade 3 or 4 infections and febrile

PFS was 5.4 months (95% CI, 3.5–7.2 months), and median OS was 10.9 months (95% CI, 9.0–13.8 months). Key grade ≥3 treatment-related AEs were neutropenia (35%), leukopenia (18%), anemia (14%), diarrhea (10%), and febrile neutropenia (10%). Six percent

, opportunistic infections, and febrile neutropenia. NCCN Recommendations Preferred Regimens Acalabrutinib, ibrutinib, and VenR are included with a category 1 recommendation, 20 – 22 , 36 zanubrutinib is included with a category 2A recommendation, 31 and

febrile neutropenia (19% vs 11%, respectively), mandating the use of growth factor support with this regimen. 43 , 44 Furthermore, the rate of pulmonary toxicity in the control group does not reflect that of modern management, given that bleomycin may be

with DLBCL refractory to first-line treatment were excluded from this study. Neutropenia (48%), thrombocytopenia (17%), and febrile neutropenia (12%) were the most common grade ≥3 hematologic toxicities. Most nonhematologic adverse events were grade 1

-CSF). It is approved for all indications of filgrastim to treat patients with (1) nonmyeloid malignancy receiving myelosuppressive chemotherapy with an intermediate- or high-risk of febrile neutropenia; (2) acute myeloid leukemia receiving induction or